Latest Insider Transactions at Johnson & Johnson (JNJ)
This section provides a real-time view of insider transactions for Johnson & Johnson (JNJ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of JOHNSON & JOHNSON to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of JOHNSON & JOHNSON's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Bona fide gift
|
Indirect |
68,835
+50.0%
|
-
|
|
Oct 17
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Bona fide gift
|
Direct |
68,835
-100.0%
|
-
|
|
Aug 30
2024
|
Robert J Decker VP Corporate Controller |
SELL
Open market or private sale
|
Direct |
5,635
-22.9%
|
$929,775
$165.06 P/Share
|
|
Aug 30
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,635
+18.63%
|
$563,500
$100.06 P/Share
|
|
Jul 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,018
-20.19%
|
$737,646
$147.16 P/Share
|
|
Jul 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
9,809
+28.3%
|
-
|
|
May 22
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Bona fide gift
|
Direct |
55
-0.08%
|
-
|
|
May 01
2024
|
John C Reed EVP, Innovative Medicine, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
10,984
-48.69%
|
$1,581,696
$144.59 P/Share
|
|
May 01
2024
|
John C Reed EVP, Innovative Medicine, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
22,255
+49.66%
|
-
|
|
Mar 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Open market or private sale
|
Direct |
8,891
-37.15%
|
$1,440,342
$162.16 P/Share
|
|
Feb 13
2024
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
86
-0.45%
|
$13,502
$157.85 P/Share
|
|
Feb 13
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
313
+1.62%
|
-
|
|
Feb 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
209
-0.87%
|
$32,813
$157.85 P/Share
|
|
Feb 13
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
408
+1.66%
|
-
|
|
Feb 13
2024
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-2.75%
|
$37,052
$157.85 P/Share
|
|
Feb 13
2024
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+7.06%
|
-
|
|
Feb 13
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
1,507
-0.41%
|
$236,599
$157.85 P/Share
|
|
Feb 13
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
3,470
+0.94%
|
-
|
|
Feb 13
2024
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
427
-1.09%
|
$67,039
$157.85 P/Share
|
|
Feb 13
2024
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+2.09%
|
-
|
|
Feb 13
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-0.42%
|
$74,418
$157.85 P/Share
|
|
Feb 13
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
925
+0.82%
|
-
|
|
Feb 13
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
250
-1.88%
|
$39,250
$157.85 P/Share
|
|
Feb 13
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
499
+3.62%
|
-
|
|
Feb 13
2024
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-1.32%
|
$30,615
$157.85 P/Share
|
|
Feb 13
2024
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
447
+2.94%
|
-
|
|
Feb 13
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
666
-0.43%
|
$104,562
$157.85 P/Share
|
|
Feb 13
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
1,302
+0.83%
|
-
|
|
Feb 13
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
773
-1.11%
|
$121,361
$157.85 P/Share
|
|
Feb 13
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,780
+2.49%
|
-
|
|
Feb 13
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
333
-0.4%
|
$52,281
$157.85 P/Share
|
|
Feb 13
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+0.78%
|
-
|
|
Feb 12
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,066
-7.94%
|
$1,109,362
$157.4 P/Share
|
|
Feb 12
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,813
+7.07%
|
-
|
|
Feb 12
2024
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.71%
|
$82,111
$157.4 P/Share
|
|
Feb 12
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,912
+4.67%
|
-
|
|
Feb 12
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
2,887
-18.41%
|
$453,259
$157.4 P/Share
|
|
Feb 12
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
5,736
+14.92%
|
-
|
|
Feb 12
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
15,900
-4.21%
|
$2,496,300
$157.4 P/Share
|
|
Feb 12
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
36,618
+4.58%
|
-
|
|
Feb 12
2024
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,695
-10.59%
|
$266,115
$157.4 P/Share
|
|
Feb 12
2024
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,456
+14.07%
|
-
|
|
Feb 12
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,019
-5.92%
|
$1,101,983
$157.4 P/Share
|
|
Feb 12
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,960
+5.84%
|
-
|
|
Feb 12
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
13,403
-8.0%
|
$2,104,271
$157.4 P/Share
|
|
Feb 12
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
26,202
+7.12%
|
-
|
|
Feb 12
2024
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,034
-11.54%
|
$162,338
$157.4 P/Share
|
|
Feb 12
2024
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+13.32%
|
-
|
|
Feb 12
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,816
-13.74%
|
$1,698,112
$157.4 P/Share
|
|
Feb 12
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,835
+13.64%
|
-
|